press center press release

NASDAQ STOCKHOLM WELCOMES XBRANE BIOPHARMA TO FIRST NORTH

Published

Stockholm, February 3, 2016 — Nasdaq (Nasdaq: NDAQ) announces that the trading in Xbrane Biopharma AB’s shares (short name: XBRANE) commenced today on Nasdaq First North in Stockholm. Xbrane belongs to the health care sector and is the 2nd company to be admitted to trading on Nasdaq’s Nordic markets* in 2016.

Xbrane is a Swedish biopharmaceutical company specialized in High Demand Complex Generics. The company has strong expertise in two niche pharmaceutical fields; developing bio generics for controlled release drugs and proprietary high-yield protein expression technology for the development of biosimilars. The goal is to become a global leader within the company’s portfolio of High Demand Complex Generics currently consisting of 8 drug candidates. Headquartered in Stockholm, Sweden, Xbrane has in-house research and development facilities in Sweden and Italy. For more information, please visit www.xbrane.com.

“We are very excited about taking yet another significant step in to becoming a major global pharmaceutical player within our niche," said Martin Åmark, CEO of Xbrane Biopharma. “With the capital raised in conjunction with the listing, we are now fully financed to execute our expansion plan and continue to grow quickly by leveraging our patented technology and unique know-how in order to provide affordable high demand complex generics for critical diseases.”

“We welcome Xbrane Biopharma to our Nordic growth market, Nasdaq First North” said Adam Kostyál, senior vice president and head of European listings at Nasdaq. “Xbrane will make a strong addition to our vibrant health care sector, and we look forward to supporting the company for many years to come.”

Xbrane Biopharma AB has appointed Avanza Bank AB as the Certified Adviser.

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.

About Nasdaq First North

Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market”

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit nasdaq.com/ambition or business.nasdaq.com.

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

Media Relations Contact:
Christina Malmberg Hägerstrand
+46 8 405 65 83
christina.hagerstrand@nasdaq.com

In This Story

Nasdaq Press Center

Read the latest press releases, request a press kit, and get in touch with our press team.

learn more